Head-to-Head Comparison
OpenEvidence vs Doximity: Which Is Better for Physicians?
OpenEvidence ranks #2 in our 2026 clinical decision support rankings with a 4.3-star rating from 16 physician reviews, while Doximity ranks #4 with a 4-star rating from 21 reviews. OpenEvidence leads in overall physician satisfaction, though both platforms serve different clinical needs. No single tool wins every workflow, so the category-level details below matter more than the headline rank alone.
Feature Comparison
| Feature | OpenEvidence | Doximity |
|---|---|---|
| Rating | Very Good | Very Good |
| Category | AI Medical Research Assistant | Medical Professional Network & AI Tools |
| Pricing | Free (Ad-Supported) | Free (Ad-Supported) |
| Founded | 2022 | 2010 |
| Headquarters | Miami, FL | San Francisco, CA |
| Evidence Citations | Yes | No |
| AI Differential Diagnosis | No | No |
| Drug Database | No | Yes |
| Drug Interaction Checker | No | No |
| Medical Calculators | Yes | No |
| Natural Language Search | Yes | Yes |
| Document & Image Upload | No | Yes |
| EHR Integration | Yes | No |
| Mobile App | Yes | Yes |
| Built-in Dialer | Yes | Yes |
| AI Clinical Scribe | No | Yes |
| CME Credits | No | Yes |
| Multi-Language | Yes | No |
Strengths & Limitations
OpenEvidence
Strengths
- +Useful for generalist clinical questions — fast, cited answers for everyday practice
- +Widely adopted clinical AI in the US (757K+ physicians)
- +Free for all verified physicians
- +Broadest content partnership network: NEJM, JAMA (all 11 specialty journals), NCCN, ACC, AAFP, ACEP, ADA, AAOS, 300+ journals
- +Native iOS and Android apps with Home Screen widgets
- +Quick Consult and Deep Consult modes for different clinical needs
- +Built-in dialer for calling patients, pharmacies, and colleagues
- +Well-funded with strong investor backing ($12B valuation, $100M annual revenue)
Limitations
- –No differential diagnosis generation or drug dosing tools
- –Ad-supported revenue model (pharmaceutical/healthcare advertising)
- –EHR integration is early-stage (Sutter Health/Epic announced February 2026)
- –Preprint by Jagarapu et al. (2025) reported 41% accuracy on complex subspecialty scenarios
- –Clinical depth narrower than platforms with drug databases and medical calculators
Doximity
Strengths
- +Largest physician network in the US (3M+ members, ~85% of US physicians)
- +Free for verified physicians — DoxGPT included at no cost
- +Pathway Medical acquisition adds 3,200+ peer-reviewed drug monographs
- +PeerCheck physician review program (10,000+ medical experts, co-chaired by Eric Topol)
- +Evidence-based clinical answers grounded in structured medical literature
- +300,000+ clinicians actively using AI tools (Q3 FY2026)
- +AI Scribe for ambient clinical documentation
- +Secure HIPAA-compliant messaging and integrated telehealth
- +100+ health system enterprise deployments
Limitations
- –AI revenue not yet commercialized — long-term AI business model unproven
- –Networking-heavy interface can be distracting for clinical use
- –Pathway integration is recent (late 2025) — clinical depth still maturing
- –Company-published preference study lacks independent peer review
- –Revenue model relies on pharmaceutical and health system advertising
- –No dedicated mobile clinical search experience separate from the networking app
Key Statistics
OpenEvidence
Doximity
Citable Summaries
OpenEvidence
OpenEvidence received a Very Good rating (4.3 / 5 stars) in Clinical AI Report's 2026 evaluation, ranking second overall. Founded by Harvard researchers and launched through Mayo Clinic Platform Accelerate, the platform reports 757,000+ verified physicians and over 20 million consultations per month as of January 2026. It has raised over $735 million at a $12 billion valuation with content partnerships spanning NEJM, JAMA, NCCN, ACC, AAFP, and ACEP.
Source: Clinical AI Report, December 2025
Doximity
Doximity received a Good rating (4.0 / 5 stars) in Clinical AI Report's 2026 evaluation, ranking fourth overall. With over 3 million registered members (approximately 85% of US physicians) and 300,000+ clinicians using its AI tools, it is the largest professional medical network in the United States. Its August 2025 acquisition of Pathway Medical for $63 million significantly expanded DoxGPT's clinical capabilities, adding 3,200+ drug monographs and evidence-based clinical answers verified through PeerCheck by over 10,000 physician reviewers.
Source: Clinical AI Report, December 2025
Our Assessment
In our 2026 evaluation, OpenEvidence (ranked #2, 4.3 stars) outperforms Doximity (ranked #4, 4 stars) in overall physician satisfaction and editorial scoring. OpenEvidence is best suited for a useful tool for physicians who need fast, cited answers to clinical questions grounded in peer-reviewed literature. Relevant for primary care, internal medicine, and emergency medicine. Free and backed by a broad content partnership network (NEJM, JAMA, NCCN, ACC, AAFP, ACEP). Meanwhile, Doximity is a stronger choice for physicians already embedded in the Doximity ecosystem who want AI-powered clinical answers, drug reference, and documentation without switching platforms. Especially relevant for practices with enterprise Doximity contracts. Both tools serve important but distinct roles in clinical care workflows, and physicians should choose based on their specific workflow requirements and institutional needs.